In data at the ASCO meeting last week, Grail showed a 1 percent false-positive rate. While that number seems likely to go down, even such a low rate can make a significant difference for patients.
While isatuximab with Celgene's Pomalyst beat Pomalyst with steroid alone, the bigger question is how it will fare on the market versus J&J's Darzalex, which will likely soon be available as an easier-to-use subcutaneous injection.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It remains unclear how many patients will relapse without the BCMA antigen, which would complicate their ability to use many CAR-T cell therapies later on. However, an expert said the drug's safety could be a challenge.
Only time will tell if a larger Phase III study will confirm data on a few dozen patients, but the two-drug combination appears to produce a higher complete response rate than than an existing doublet combination, without the associated toxicity.
In an interview at the ASCO meeting, BeiGene chief adviser Eric Hedrick said the company is well-prepared for when it likely regains global rights to tislelizumab.
The company presented end-of-Phase I data from the trial, on KTE-X19, at the ASCO meeting in Chicago Saturday.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company plans to present early data in a poster on Saturday showing no more than 1 percent of tests generated false-positive results across 12 solid tumor and blood cancers.
The biotech company plans to present Phase I data at ASCO on the drug, AMG 510, which targets KRAS mutations in solid tumors.